LAS VEGAS, Feb. 9, 2021
Increase in patient pool, expected entry of emerging therapies, and deeper penetration of these drugs in 7MM are key factors in driving Marginal Zone Lymphoma market
LAS VEGAS, Feb. 9, 2021 /PRNewswire/ -- DelveInsight's "Marginal Zone Lymphoma (MZL) Market" report provides a complete comprehension of the Marginal Zone Lymphoma, historical and forecasted epidemiology and the MZL market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Marginal Zone Lymphoma market report also proffers an analysis of recent MZL treatment practice/algorithm, market drivers, market barriers and unmet medical needs.
Some of the highlights of Marginal Zone Lymphoma Market Research Report
For additional information on Market Impact by Therapies, visit: Marginal Zone Lymphoma Market Forecast Analysis
Marginal Zone B-cell lymphoma is a group of indolent Non-Hodgkin lymphoma (NHL) B-cell lymphomas that account for approximately 5‒17% of all NHL cases. The total Non-Hodgkin lymphoma incident population in the 7MM was estimated to be 174,941 in 2020. Out of these, the total Marginal Zone Lymphoma incident population in the 7MM was 22,268 in the same year.
The Marginal Zone Lymphoma Market Report provides historical as well as forecasted epidemiological analysis segmented into:
Review a sample report for more insights @ Marginal Zone Lymphoma Market Insight
Treatment selection for an MZL patient depends on the type, stage, and location of the disease. The total MZL market is categorized into three types based on the line of therapies, first-line, second-line, and third-line of therapies. The first line treatment comprises only the supportive therapies, including rituximab monotherapy, R-CHOP/R-CVP, rituximab plus bendamustine, cytotoxic chemotherapy, antiviral therapy for hepatitis C infection, Antibiotic/PPIs.
In May 2019, the FDA approved lenalidomide (Revlimid) combined with a rituximab product for previously treated follicular lymphoma (FL) and previously-treated MZL. Moreover, in December 2019, the European Commission approved Revlimid (lenalidomide) in combination with rituximab for the treatment of adult patients with previously treated MZL. The drug is not being approved in Japan but is expected to get launched in the forecast period 2020–2030 and hence is an emerging therapy for Japan.
Revlimid is an immune-modulating therapy with proven anti-myeloma eﬀects. The drug is an oral therapy that was shown to work in 3 ways in animal models and in vitro, it aids the immune system to identify and eradicate myeloma cells. It targets and destroys myeloma cells and helps prevent new myeloma cell growth by starving them of blood.
Several pharmaceutical key players have taken the initiatives to meet the unmet needs of the present situation of the MZL market. Some of the key players are in the late and mid clinical development stages with their leading drug candidates. MZL pipeline possesses potential drugs as monotherapies as well as combination therapies.
Marginal Zone Lymphoma Emerging Therapies Along with Key Players
And several others.
Concluding thoughts on Marginal Zone Lymphoma Market Growth
Scope of the Marginal Zone Lymphoma Market Insight
Request for a Webex demo of the report @ Marginal Zone Lymphoma Market Size
Table of Contents
Key Insights on Marginal Zone Lymphoma
Executive Summary of Marginal Zone Lymphoma
Marginal Zone Lymphoma Market Overview at a Glance
Disease Background and Overview: Marginal Zone Lymphoma
Marginal Zone Lymphoma Case Reports
MZL Epidemiology and Patient Population
Current Marginal Zone Lymphoma Treatment and Medical Practices
Marginal Zone Lymphoma Unmet Needs
Marginal Zone Lymphoma Marketed Drugs
Revlimid (lenalidomide) in combination with rituximab: Celgene Corporation, Bristol-Myers Squibb
Imbruvica (ibrutinib): AbbVie, Janssen Biotech
Marginal Zone Lymphoma Emerging Drugs
Key Cross Competition
Umbralisib (TGR-1202): TG Therapeutics
Aliqopa (Copanlisib): Bayer
Ublituximab: TG Therapeutics
Obinutuzumab: Roche Pharma
Yescarta (axicabtagene ciloleucel): Gilead Sciences
Keytruda (Pembrolizumab): Merck Sharp & Dohme
CLR 131: Cellectar Biosciences
Parsaclisib: Innovent Biologics
Nivolumab (Oppdivo): Bristol-Myers Squibb
Calquence (acalabrutinib): Astrazeneca
Betalutin (177Lu-satetraxetan-lilotomab): Nordic Nanovector
Navitoclax (ABT-263): AbbVie
Orelabrutinib (ICP-022): InnoCare Pharma
M7583: Merck KGaA
ARQ 531: ArQule/Merck
Duvelisib: Verastem/Secura Bio
Zandelisib: MEI Pharma
LOXO-305: Loxo Oncology/Eli Lilly
SD-101: TriSalus Life Sciences
MZL Patient Journey
7MM Marginal Zone Lymphoma Market Analysis
Potential of MZL Emerging Therapies
Key Marginal Zone Lymphoma Market Forecast Assumptions
United States MZL Market Outlook
EU-5 MZL Market Outlook
Germany Market Size
France Market Size
Italy Market Size
Spain Market Size
United Kingdom Market Size
Japan MZL Market Outlook
Marginal Zone Lymphoma Market Drivers
Marginal Zone Lymphoma Market Barriers
Reimbursement and Marginal Zone Lymphoma Market Access
Browse detailed TOC with charts, figures, tables @ Marginal Zone Lymphoma Therapeutic Market
View Related Reports
DelveInsight's Marginal Zone Lymphoma - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology.
DelveInsight's Morquio Syndrome Market Insights, Epidemiology and Market Forecast - 2030 report provides detailed insights on historical and forecasted epidemiology.
DelveInsight's Diabetes Market Insights, Epidemiology and Market Forecast - 2030 report provides thorough insights on epidemiology and market trends.
DelveInsight's Buerger's Disease Market Insights, Epidemiology and Market Forecast - 2030 report provides thorough insights on epidemiology and market trends.
DelveInsight's Multiple Sclerosis- Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed understanding of historical and forecasted epidemiology.
DelveInsight's Chronic Wounds Market Insights, Epidemiology and Market Forecast - 2030 report provides detailed insights on historical and forecasted epidemiology.
DelveInsight's Smoking Cessation - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology.
DelveInsight's Radiation Toxicity Market Insights, Epidemiology and Market Forecast - 2030 report provides an in-depth understanding of historical and forecasted epidemiology.
DelveInsight's Indolent Lymphoma - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology.
DelveInsight's 'ICOS-Next Generation Immunotherapy- Competitive Landscape and Market Forecast–2035' report delivers an in-depth understanding of the ICOS as well as the market trends.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.